Teikoplanin AptaPharma 400 mg prašak i otapalo za otopinu za injekciju/infuziju Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

teikoplanin aptapharma 400 mg prašak i otapalo za otopinu za injekciju/infuziju

apta medica internacional d.o.o., likozarjeva ulica 6, ljubljana, slovenija - teikoplanin - prašak i otapalo za otopinu za injekciju / infuziju - urbroj: jedna bočica sadrži 400 mg teikoplanina

octaplasLG 45-70 mg/ml otopina za infuziju Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

octaplaslg 45-70 mg/ml otopina za infuziju

octapharma (ip) sprl, allee de la recherche 65, anderlecht, belgija - адррес proteini ljudske plazme koji djeluju protiv inhibitora koagulacijskog faktora viii u - otopina za infuziju - 45-70 mg/ml - urbroj: 1 ml otopine za infuziju sadrži 45-70 mg proteina ljudske plazme

octaplasLG 45-70 mg/ml prašak i otapalo za otopinu za infuziju Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

octaplaslg 45-70 mg/ml prašak i otapalo za otopinu za infuziju

octapharma (ip) sprl, allee de la recherche 65, anderlecht, belgija - ljudska plazma - prašak i otapalo za otopinu za infuziju - urbroj: jedna bočica s praškom sadrži 9 - 14 g proteina ljudske plazme specifičnih za krvne grupe ab0. nakon rekonstitucije sa 190 ml otapala, otopina sadrži 45-70 mg/ml proteina ljudske plazme specifičnih za krvne grupe ab0

Karmustin Teva 100 mg prašak i otapalo za koncentrat za otopinu za infuziju Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

karmustin teva 100 mg prašak i otapalo za koncentrat za otopinu za infuziju

teva b.v., swensweg 5, haarlem, nizozemska - karmustin - prašak i otapalo za koncentrat za otopinu za infuziju - 100 mg - urbroj: jedna bočica praška sadrži 100 mg karmustina

Noxafil Europska Unija - hrvatski - EMA (European Medicines Agency)

noxafil

merck sharp and dohme b.v - posakonazol - candidiasis; mycoses; coccidioidomycosis; aspergillosis - antimikotika za sustavnu uporabu - noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 i 5. 1):- invasive aspergillosisnoxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections  4. 2 i 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. Огнеупорность definira kao progresiju infekcije ili nedostatak poboljšanja nakon što je minimum 7 dana do terapijske doze učinkovit antifungalna terapija. noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4. 2 i 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 i 5. 1):- invasive aspergillosisnoxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adult and paediatric patients from 2 years of age (see sections 4. 2 i 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. Огнеупорность definira kao progresiju infekcije ili nedostatak poboljšanja nakon što je minimum 7 dana do terapijske doze učinkovit antifungalna terapija. noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in the following adult and paediatric patients from 2 years of age (see sections 4. 2 i 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (gvhd) and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil gastro resistant powder and solvent for oral suspension is indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age (see sections 4. 2 i 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. Огнеупорность definira kao progresiju infekcije ili nedostatak poboljšanja nakon što je minimum 7 dana do terapijske doze učinkovit antifungalna terapija. noxafil gastro-resistant powder and solvent for oral suspension is indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2  years of age:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high  risk of developing invasive fungal infections;- haematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high  risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products;- oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor. Огнеупорность definira kao progresiju infekcije ili nedostatak poboljšanja nakon što je minimum 7 dana do terapijske doze učinkovit antifungalna terapija. noxafil oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.

Octanate 1000 IU prašak i otapalo za otopinu za injekciju Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

octanate 1000 iu prašak i otapalo za otopinu za injekciju

jana pharm d.o.o., lopašićeva 6, zagreb, hrvatska - koagulacijski faktor viii, ljudski - prašak i otapalo za otopinu za injekciju - 1000 iu/bočici - urbroj: svaka bočica nominalno sadrži 1000 iu ljudskog koagulacijskog faktora viii

Octanate 250 IU prašak i otapalo za otopinu za injekciju Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

octanate 250 iu prašak i otapalo za otopinu za injekciju

jana pharm d.o.o., lopašićeva 6, zagreb, hrvatska - koagulacijski faktor viii, ljudski - prašak i otapalo za otopinu za injekciju - 250 iu/bočici - urbroj: svaka bočica nominalno sadrži 250 iu ljudskog koagulacijskog faktora viii

Octanate 500 IU prašak i otapalo za otopinu za injekciju Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

octanate 500 iu prašak i otapalo za otopinu za injekciju

jana pharm d.o.o., lopašićeva 6, zagreb, hrvatska - koagulacijski faktor viii, ljudski - prašak i otapalo za otopinu za injekciju - 500 iu/bočici - urbroj: svaka bočica nominalno sadrži 500 iu ljudskog koagulacijskog faktora viii

OCTANATE LV 100 i.j./1 mL prašak i rastvarač za rastvor za injekciju Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

octanate lv 100 i.j./1 ml prašak i rastvarač za rastvor za injekciju

remedia d.o.o. - koagulacije faktor viii, a humanitarne - prašak i rastvarač za rastvor za injekciju - 100 i.j./1 ml - 1 ml rastvora za injekciju sadrži: 100 i.j. humanog faktora koagulacije viii

OCTANATE LV 200 i.j./1 mL prašak i rastvarač za rastvor za injekciju Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

octanate lv 200 i.j./1 ml prašak i rastvarač za rastvor za injekciju

remedia d.o.o. - koagulacije faktor viii, a humanitarne - prašak i rastvarač za rastvor za injekciju - 200 i.j./1 ml - 1 ml rastvora za injekciju sadrži: 200 i.j. humanog faktora koagulacije viii